Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The company’s largest center for medical device applications, serving the entire Asian market
EBITDA before special items decreases to €4.08 billion (7.4%)
Rising demands and advancements in eye care drive growth
Subscribe To Our Newsletter & Stay Updated
